Literature DB >> 11802587

Safety considerations for new vaccine development.

S S Ellenberg1.   

Abstract

Vaccines are highly effective and extremely safe. Although most known vaccine reactions are minor (e.g. fever, injection site pain or swelling), rare but serious reactions such as vaccine-associated paralytic polio do occur. When large populations are vaccinated, some adverse health events may occur by chance shortly after vaccination. It is difficult to determine whether these are truly coincidental or attributable to the vaccine. The most reliable way to assess causality is in a controlled study, but clinical trials of new vaccines are typically too small to detect rare but serious effects. If the size of these trials were increased, much more could be learned about the safety of a vaccine prior to its exposure to entire populations. This information would increase confidence in the safety of vaccines, would be a valuable resource for assessing spontaneous reports of adverse events after licensure, and would reduce the risk of licensing a new vaccine that had the potential to cause severe injury to a small proportion of vaccinees.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11802587     DOI: 10.1002/pds.616

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  5 in total

1.  Evaluating the safety of new vaccines: summary of a workshop.

Authors:  Susan S Ellenberg; Mary A Foulkes; Karen Midthun; Karen L Goldenthal
Journal:  Am J Public Health       Date:  2005-05       Impact factor: 9.308

2.  Adverse event detection in drug development: recommendations and obligations beyond phase 3.

Authors:  Jesse A Berlin; Susan C Glasser; Susan S Ellenberg
Journal:  Am J Public Health       Date:  2008-06-12       Impact factor: 9.308

3.  Monitoring the safety of vaccines: assessing the risks.

Authors:  Susan S Ellenberg; Miles M Braun
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

4.  Safety of 9-valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014-2017.

Authors:  Claudia S Landazabal; Pedro L Moro; Paige Lewis; Saad B Omer
Journal:  Vaccine       Date:  2019-01-16       Impact factor: 3.641

5.  Size of clinical trials and Introductory prices of prophylactic vaccine series.

Authors:  Steven H Weinberg; Amy T Butchart; Matthew M Davis
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.